Stockscreener 앱 받기
0.5703
8.80%
-0.055
시간 외 거래:
.57
-0.0003
-0.05%
전일 마감가:
$0.6253
열려 있는:
$0.65
하루 거래량:
171.18K
Relative Volume:
0.05
시가총액:
$2.02M
수익:
$1.31M
순이익/손실:
$-8.38M
주가수익비율:
-0.0556
EPS:
-10.2555
순현금흐름:
$-6.38M
1주 성능:
-20.10%
1개월 성능:
-6.51%
6개월 성능:
-46.20%
1년 성능:
-79.67%
1일 변동 폭
$0.57
$0.65
1주일 범위
$0.57
$0.76
52주 변동 폭
$0.4549
$6.18
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
명칭
Scinai Immunotherapeutics Ltd Adr
전화
972-8-9302529
주소
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
0.5703 | 2.21M | 1.31M | -8.38M | -6.38M | -10.26 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scinai Immunotherapeutics Ltd Adr 주식(SCNI)의 최신 뉴스
Tangible book value per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
NASDAQ gains over 100 points; Intel shares jump after strong Q1 results - MSN
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today - Sahm
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - Finviz
Nasdaq Gains Over 100 Points; Intel Shares Jump After Strong Q1 Results - Benzinga
Scinai raises $2.61M in private placement to expand CDMO unit - Investing.com
Scinai raises $2.61M in private placement to expand CDMO unit By Investing.com - Investing.com South Africa
Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Sahm
Scinai Completes Corporate Reorganization Separating CDMO and R&D Operations - Contract Pharma
Scinai completes corporate reorganization, separates CDMO unit By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Total debt per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Scinai completes corporate reorganization, separates CDMO unit - Investing.com
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - Barchart.com
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Sahm
Scinai Immunotherapeutics (NASDAQ: SCNI) details going concern, CDMO and NanoAb risks - Stock Titan
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 - Finviz
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Barchart.com
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Finviz
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Benzinga
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Finviz
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Barchart.com
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Enerflex (NYSE:EFXT) Shares Gap Up Following Dividend Announcement - Defense World
Scinai receives expanded grant for robotic manufacturing system - Investing.com
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - Finviz
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - Barchart
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 3.1% – Here’s Why - Defense World
Scinai Immunotherapeutics Reports Growth and Pipeline Progress - MSN
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Finviz
Working capital per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView — Track All Markets
Coca-Cola HBC (OTCMKTS:CCHGY) Trading 3.7% Higher – Should You Buy? - Defense World
PCCW (OTCMKTS:PCWLF) Trading Down 7.9% – Here’s Why - Defense World
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest - Defense World
Scinai Immunotherapeutics (NASDAQ:SCNI) Stock Price Down 1.3% – Should You Sell? - Defense World
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView — Track All Markets
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next? - Defense World
Scinai reports revenue growth as CDMO business expands By Investing.com - Investing.com India
Scinai reports revenue growth as CDMO business expands - Investing.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Barchart.com
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
SCNI | Scinai Immunotherapeutics Ltd. ADR SEC Filings - MarketWatch
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai Immunotherapeutics schedules annual meeting for December 22 By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Finviz
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Finviz
Scinai Immunotherapeutics Ltd Adr (SCNI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):